Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Overview
Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.
Technology and Innovation
Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.
Product Portfolio and Market Position
The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.
Patient and Physician Support
An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.
Global Reach and Regulatory Milestones
Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.
Competitive Landscape and Differentiators
Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.
Conclusion
Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.
Nevro Corp. and Boston Scientific Corp. have resolved their intellectual property litigation through a settlement. This agreement allows Boston Scientific to operate with its current products utilizing features below 1,500 Hz while granting Nevro similar freedoms. Nevro will license paresthesia-free therapy technology to Boston Scientific, and vice versa. The settlement also includes a net payment of $85 million from Boston Scientific to Nevro, concluding all ongoing litigations between the two parties.
Nevro Corp. (NYSE: NVRO), a medical device company based in Redwood City, California, will have CFO Rod MacLeod present at the Canaccord Genuity 42nd Annual Growth Conference. The event is scheduled for August 10, 2022, at 2:30 pm Eastern Time, in Boston, MA. Investors can access a live webcast and subsequent recording on Nevro's website. Nevro specializes in innovative solutions for chronic pain, including the proprietary 10 kHz Therapy, which has benefited over 80,000 patients worldwide. For more details, visit www.nevro.com.
Nevro Corp. (NVRO), a global medical device company, will report its financial results for Q2 2022 after market close on August 3, 2022. A conference call to discuss the results will take place at 1:30 pm PT / 4:30 pm ET. Investors can tune in by calling (888) 330-2443 or +1 (240) 789-2728 with Conference ID: 3583097. Nevro specializes in innovative solutions for chronic pain, including its proprietary 10 kHz Therapy, impacting over 80,000 patients globally. For further updates, visit Nevro's website.
Nevro Corp. (NYSE: NVRO) reported 12-month results from the SENZA-PDN trial, showing extensive pain relief and significant improvements in health-related quality of life (HRQoL) for patients with painful diabetic neuropathy (PDN) treated with 10 kHz spinal cord stimulation. Key findings include a 2.5- to 4.5-fold improvement in HRQoL metrics compared to minimal clinical importance, with over 70% of patients indicating better overall health. The data supports the product's potential for expanding market access and payer coverage, with a total addressable market of approximately $3.5 billion to $5.0 billion.
Nevro Corp. (NYSE: NVRO) announced positive results from the SENZA-PDN trial at the ADA 82nd Scientific Sessions. The 24-month follow-up demonstrated that 10 kHz spinal cord stimulation (SCS) therapy provides significant pain relief for patients with painful diabetic neuropathy (PDN). Key findings include an 84% responder rate, a 77% average reduction in pain, and 89% patient satisfaction. The study involved 216 patients across 18 U.S. centers, marking it as the largest RCT of its kind. Nevro plans to release additional data in Q4 2022 and anticipates expanding treatment options for PDN patients.
Nevro Corp. (NYSE: NVRO) announced that the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial data will be presented at the ADA's 82nd Scientific Sessions from June 3-7, 2022. The presentation will include 24-month follow-up results from the trial, which compares Nevro's 10 kHz spinal cord stimulation (SCS) therapy plus medical management to standard care. Previous results showed significant pain relief and improved quality of life. Nevro anticipates complete 24-month data availability in Q4 2022 for further presentation.
Nevro Corp. (NYSE: NVRO) reported first-quarter 2022 revenue of $87.8 million, a 1% decline from the previous year but a 7% increase compared to 2019. U.S. trial and permanent implant procedures grew by 10% and 2% respectively. The company experienced a net loss from operations of $32.8 million. For Q2 2022, Nevro expects revenues between $103 million and $106 million, and maintains full-year guidance of $415 million to $430 million. Positive payer coverage from UnitedHealthcare and Noridian could enhance access to its therapies.
Nevro Corp. (NYSE: NVRO) will report its first quarter 2022 financial results after market close on May 4, 2022. Following the report, management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested investors can dial (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using Conference ID: 3583097. The call will be accessible via a live webcast and archived on Nevro's website, www.nevro.com.
Nevro Corp. announced an update from Noridian, the Medicare Administrative Contractor, which includes two new ICD-10 codes for Painful Diabetic Neuropathy (PDN) effective retroactively from January 1, 2022. This update increases access to Nevro's 10 kHz Therapy for PDN patients, expanding coverage from approximately 25% to 43% of PDN patients in the U.S. Noridian oversees Medicare coverage in several Western states. Nevro's CEO stated that this advancement will facilitate better access and is working to ensure further coverage by other payers.
Nevro Corp. reported a 4Q 2021 revenue of $102.8 million, down 6% year-over-year and 10% from 2019. The net loss was $26.2 million, with a non-GAAP adjusted EBITDA of - $7.5 million. U.S. revenue decreased 7% to $88.4 million, while international revenue fell 5% to $14.3 million. For 2022, Nevro projects first quarter revenue of $85-$87 million and annual revenue of $415-$430 million, anticipating impacts from COVID-19. Additionally, it received FDA approval for a new therapy and a positive coverage decision from UnitedHealthcare.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
What is Nevro Corp's primary business?
Which products form the core of Nevro's portfolio?
How does Nevro's spinal cord stimulation system work?
In which markets are Nevro's products available?
What role does technology play in Nevro's treatments?
How does Nevro support its patients and healthcare providers?
What differentiates Nevro from other pain management companies?
What conditions do Nevro's therapies target?
